Status | Study |
Active, not recruiting |
Study Name: A Study Evaluating Ultratrace Iobenguane I131 in Patients With Malignant Relapsed/Refractory Pheochromocytoma/Paraganglioma Condition: Pheochromocytoma Paraganglioma Date: 2009-04-01 Interventions: Radiation: Ultratrace® Iobenguane I131 Each subject will be administered 3 mCi to 6 mCi Ultratrace& |
Completed |
Study Name: Study Of Sunitinib In Patients With Recurrent Paraganglioma/Pheochromocytoma Condition: Paraganglioma Pheochromocytoma Date: 2009-02-12 Interventions: Drug: Sunitinib 50 mg oral dose daily for 4 weeks, 2 week rest period (repeating 6 week cycles) |
Completed |
Study Name: Phase 1 Study of Iobenguane (MIBG) I 131 in Patients With Malignant Pheochromocytoma/Paraganglioma Condition: Pheochromocytoma Paraganglioma Date: 2007-04-09 Interventions: Drug: Ultratrace Iobenguane (MIBG) I 131 Phase I: Dose escalation protocol Phase II: Treatment schedule |
Completed |
Study Name: ULTRATRACE Iobenguane I 131 in Patients With Malignant Pheochromocytoma, Paraganglioma, or Metastatic Carcinoid Condition: Pheochromocytoma Paraganglioma Date: 2006-06-17 Interventions: Drug: Ultratrace iobenguane I 131 |
Completed |
Study Name: Hereditary Paraganglioma: Evaluation of Screening Methods to Detect Tumors in SDH Positive Carriers Condition: Paraganglioma Pheochromocytoma Date: 2005-09-12 Interventions: Procedure: diagnosis methods |
Recruiting |
Study Name: Diagnosis of Pheochromocytoma Condition: Pheochromocytoma Date: 2000-03-02 |